Related Experiment Video

Updated: Sep 23, 2026

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
12:27

The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice

Published on: April 2, 2014

Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa

Linda D Thomas1, Jennelle M Kyd, David A Bastin

  • 1Gadi Research Centre, Division of Science and Design, University of Canberra, 2601, Canberra, ACT, Australia. linda.thomas@canberra.edu.au

FEMS Immunology and Medical Microbiology
|July 2, 2003
PubMed

Insights

Researchers identified six Pseudomonas aeruginosa proteins that, when used as antigens, significantly enhanced bacterial clearance in a rat lung infection model. This finding supports their potential as vaccine candidates against P. aeruginosa infections.

Area of Science:

  • Bacteriology
  • Immunology
  • Vaccine Development

Background:

  • Pseudomonas aeruginosa is an opportunistic pathogen causing severe lung infections, particularly in cystic fibrosis patients.
  • Increasing antibiotic resistance in P. aeruginosa necessitates novel therapeutic strategies, including vaccines.
  • The bacterium employs immunomodulatory products for survival within the host lung.

Purpose of the Study:

  • To identify and evaluate non-integral protein antigens from P. aeruginosa for their vaccine potential.
  • To assess the efficacy of these antigens in enhancing bacterial clearance in a preclinical model.
  • To determine the protective capabilities of cytosolic proteins against P. aeruginosa lung infections.

Main Methods:

  • Purification and N-terminal amino acid sequencing of six non-integral P. aeruginosa proteins (Pa13, azurin, ACP, amidase, aminopeptidase, KatE).
  • Assessment of antigen efficacy using a rat model of acute pulmonary infection.
  • Evaluation of both mucosal and parenteral immunization routes.

Main Results:

  • Mucosal immunization with four antigens significantly enhanced P. aeruginosa clearance from lung lavage fluid and tissue.
  • KatE, aminopeptidase, and amidase showed the greatest bacterial clearance efficacy.
  • Recombinant amidase and aminopeptidase maintained enhanced clearance; parenteral aminopeptidase also proved effective.

Conclusions:

  • Non-integral outer membrane proteins of P. aeruginosa possess antigenic and protective properties.
  • Selected antigens, particularly KatE, aminopeptidase, and amidase, are promising candidates for P. aeruginosa vaccine development.
  • Further investigation of these proteins is warranted for their inclusion in a comprehensive vaccine strategy.

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: